Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435650 | 1.00 | GRIN1 (0.52) | GRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL4641578 | 0.89 | GRIN1 (0.52) | GRIN1GRIN2B | |
| SCHEMBL4677159 | 0.88 | MEN1 (0.46) | GRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL4641458 | 0.88 | MEN1 (0.46) | GRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL4640599 | 0.87 | MEN1 (0.45) | GRIN1GRIN2BMEN1KMT2A | |
| SCHEMBL4640502 | 0.86 | TRPV1 (0.44) | — | |
| SCHEMBL5925155 | 0.86 | TRPV1 (0.44) | — | |
| SCHEMBL5273882 | 0.83 | — | — | |
| SCHEMBL4640597 | 0.83 | — | — | |
| SCHEMBL3833265 | 0.80 | MEN1 (0.43) | GRIN1GRIN2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | claimed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1824837-B1 | SUBSTITUTED N-SULFONYLAMINOBENZYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7214824-B2 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | GRIN1 171/4885GRIN2B 465/4885MEN1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.